• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    4/15/24 8:07:12 AM ET
    $ALLR
    $ATHE
    $BMRA
    $COCH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALLR alert in real time by email

    Gainers

    • Soligenix (NASDAQ:SNGX) stock increased by 95.1% to $0.75 during Monday's pre-market session. The company's market cap stands at $7.9 million.
    • Longeveron (NASDAQ:LGVN) shares increased by 51.47% to $2.56. The company's market cap stands at $8.1 million.
    • Cartesian Therapeutics (NASDAQ:RNAC) shares moved upwards by 40.02% to $27.15. The company's market cap stands at $482.7 million.
    • Biomerica (NASDAQ:BMRA) shares rose 21.98% to $1.01. The company's market cap stands at $16.9 million. As per the press release, Q3 earnings came out yesterday.
    • Allarity Therapeutics (NASDAQ:ALLR) shares increased by 21.42% to $2.55. The company's market cap stands at $1.2 million.
    • Envoy Medical (NASDAQ:COCH) stock moved upwards by 18.81% to $6.0. The company's market cap stands at $117.5 million.

    Losers

    • Marinus Pharma (NASDAQ:MRNS) stock decreased by 74.5% to $1.92 during Monday's pre-market session. The market value of their outstanding shares is at $105.4 million.
    • TRACON Pharma (NASDAQ:TCON) shares decreased by 17.8% to $1.94. The market value of their outstanding shares is at $4.4 million.
    • Neumora Therapeutics (NASDAQ:NMRA) shares declined by 17.04% to $11.25. The company's market cap stands at $1.7 billion.
    • PaxMedica (NASDAQ:PXMD) stock fell 16.57% to $0.7. The market value of their outstanding shares is at $5.1 million.
    • Alterity Therapeutics (NASDAQ:ATHE) stock fell 15.65% to $2.48. The market value of their outstanding shares is at $21.6 million.
    • SINTX Techs (NASDAQ:SINT) shares decreased by 15.19% to $0.02. The market value of their outstanding shares is at $2.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLR
    $ATHE
    $BMRA
    $COCH

    CompanyDatePrice TargetRatingAnalyst
    Neumora Therapeutics Inc.
    $NMRA
    2/17/2026Mkt Perform → Outperform
    William Blair
    Neumora Therapeutics Inc.
    $NMRA
    1/12/2026$8.00Outperform
    Leerink Partners
    Neumora Therapeutics Inc.
    $NMRA
    12/1/2025$7.00Sector Perform → Outperform
    RBC Capital Mkts
    Neumora Therapeutics Inc.
    $NMRA
    10/27/2025$14.00Neutral → Buy
    Guggenheim
    Neumora Therapeutics Inc.
    $NMRA
    9/16/2025Neutral → Underweight
    Analyst
    Allarity Therapeutics Inc.
    $ALLR
    7/28/2025$9.00Buy
    Ascendiant Capital Markets
    Cartesian Therapeutics Inc.
    $RNAC
    7/9/2025$38.00Outperform
    Wedbush
    Neumora Therapeutics Inc.
    $NMRA
    4/2/2025$1.00Buy → Underperform
    BofA Securities
    More analyst ratings

    $ALLR
    $ATHE
    $BMRA
    $COCH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Officer Aurora Daljit Singh sold $21,917 worth of shares (6,165 units at $3.56), decreasing direct ownership by 7% to 82,770 units (SEC Form 4)

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    2/19/26 5:07:13 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President Pinto Joshua sold $21,093 worth of shares (5,967 units at $3.54), decreasing direct ownership by 9% to 57,783 units (SEC Form 4)

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    2/19/26 5:06:16 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLR
    $ATHE
    $BMRA
    $COCH
    SEC Filings

    View All

    Envoy Medical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

    8-K - Envoy Medical, Inc. (0001840877) (Filer)

    2/27/26 9:11:14 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

    2/19/26 8:00:48 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SiNtx Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Sintx Technologies, Inc. (0001269026) (Filer)

    2/18/26 8:35:38 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $ALLR
    $ATHE
    $BMRA
    $COCH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Patel Mona Chetan bought $125,000 worth of shares (312,500 units at $0.40), increasing direct ownership by 1,562% to 332,500 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:51:51 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $ALLR
    $ATHE
    $BMRA
    $COCH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy

    Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company's peer-reviewed randomized controlled trial.CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.Physician Perspective: New interview with Gastroenterologist Dr. Dak Patel about inFoods IBS in clinical use now available at https://investors.biomerica.com/events-and-presentations/default.aspx IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), an innovator in diagnostic-guided therapy, today announced respo

    2/26/26 8:19:00 AM ET
    $BMRA
    $HSIC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical Specialities

    Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

    PRINCETON, N.J., Feb. 26, 2026 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) provided a positive recommendation on the Company's request for orphan drug designation for dusquetide (the active pharmaceutical ingredient in SGX945) for the treatment of Behçet's Disease, following review of the recently published Phase 2a clinical results demonstrating biological efficacy and safety in patients with Behçet's Disease.

    2/26/26 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell

    MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic aging-related conditions, today announced that results of its Phase 2b clinical trial were published today in Cell Stem Cell, a Cell Press Journal. The Phase 2b results demonstrated that intravenous laromestrocel, a mesenchymal stem cell product, improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. The full publication is available on the Cell Stem Cell website here. Laromestrocel (LOMECEL-B®) is a proprietary, scalable, allogeneic

    2/25/26 11:05:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $ATHE
    $BMRA
    $COCH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Neumora Therapeutics upgraded by William Blair

    William Blair upgraded Neumora Therapeutics from Mkt Perform to Outperform

    2/17/26 7:22:19 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Leerink Partners initiated coverage on Neumora Therapeutics with a new price target

    Leerink Partners initiated coverage of Neumora Therapeutics with a rating of Outperform and set a new price target of $8.00

    1/12/26 8:18:29 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neumora Therapeutics upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Neumora Therapeutics from Sector Perform to Outperform and set a new price target of $7.00

    12/1/25 8:13:43 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLR
    $ATHE
    $BMRA
    $COCH
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

    Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev

    2/18/26 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

    − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers to explore non-dilutive pathways to fund Phase 3 development.Board and executive leadership strengthened to support Alterity through its next stage of clinical development, partnering and comme

    1/30/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $ATHE
    $BMRA
    $COCH
    Financials

    Live finance-specific insights

    View All

    Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation

    NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect  NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specified population with elevated anxiety NMRA-511 demonstrated a favorable tolerability and safety profile Neumora plans to evaluate higher doses of NMRA-511 via initiation of a multiple ascending dose expansion cohort in 2026 Company to host conference call today at 8:00 am ET WATERTOWN, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms

    1/5/26 6:30:00 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

         Received FDA Fast Track designation for stenoparib in advanced ovarian cancer Reported landmark median overall survival now exceeding 25 months in ongoing Phase 2 trialAdvanced DRP® platform through new licensing agreement TARPON SPRINGS, Fla., November 14, 2025 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the third quarter ended September 30, 2025. "The third quarter of 2025 was another milestone period for Allarity as we ac

    11/14/25 9:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SINTX Reports Pivotal Third Quarter Business Update and Financial Highlights Driven by FDA Clearance, Product and IP Portfolio Expansions and Increased Operational Efficiencies

    Company underscores its strengthened liquidity, cost reductions, and first revenue recorded from OsseoSculpt™  SALT LAKE CITY, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon-nitride–based medical technologies, today provided a business update reporting third quarter financial results in conjunction with the filing the Company's Form 10-Q for the quarter ended September 30, 2025. During the third quarter and subsequent weeks, SINTX advanced a focused commercialization plan centered on infection-resistant silicon nitride devices and polymer composites, while tighteni

    11/13/25 8:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $ALLR
    $ATHE
    $BMRA
    $COCH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Neumora Therapeutics Inc.

    SC 13D/A - Neumora Therapeutics, Inc. (0001885522) (Subject)

    11/22/24 5:33:43 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cartesian Therapeutics Inc.

    SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

    11/18/24 9:44:37 PM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

    SC 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

    11/15/24 10:35:20 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care